Inventor
CURTIS NEIL ROY
GB27 patents
⚠️ This page may combine multiple inventors who share the name “CURTIS NEIL ROY”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MERCK SHARP & DOHME
24 patentsUS6172077B1Jan 9, 2001
Spiro-azacyclic derivatives and their use as therapeutic agents
MERCK SHARP & DOHME149 citations97
US6114315ASep 5, 2000
Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety
MERCK SHARP & DOHME26 citations92
US5977104ANov 2, 1999
Use of NK-1 receptor antagonists for treating bipolar disorders
MERCK SHARP & DOHME29 citations92
US5952315ASep 14, 1999
Use of NK-1 receptor antagonists for treating bipolar disorders
MERCK SHARP & DOHME34 citations92
US5712285AJan 27, 1998
Pyrrolo-pyridine derivatives
MERCK SHARP & DOHME48 citations92
US5700809ADec 23, 1997
Pyrrolo-pyridine derivatives
MERCK SHARP & DOHME49 citations92
US6395766B1May 28, 2002
Tetrahydroindolone derivatives as gabaaalpha5 ligands for enhancing cognition
MERCK SHARP & DOHME27 citations91
US6071928AJun 6, 2000
Spiro-piperidine derivatives and their use as therapeutic agents
MERCK SHARP & DOHME21 citations83
US6271230B1Aug 7, 2001
Use of NK-1 receptor antagonists for treating cognitive disorders
MERCK SHARP & DOHME6 citations74
US6071927AJun 6, 2000
Spiro-piperidine derivatives and their use as therapeutic agents
MERCK SHARP & DOHME13 citations74
US5925627AJul 20, 1999
Use of NK-1 receptor antagonists for treating movement disorders
MERCK SHARP & DOHME7 citations74
US5700802ADec 23, 1997
Furopyridine derivatives
MERCK SHARP & DOHME12 citations74
US6100256AAug 8, 2000
Use of NK-1 receptors antagonists for treating schizophrenic disorders
MERCK SHARP & DOHME7 citations73
US5849765ADec 15, 1998
Tetrahydropyridine derivatives as dopamine receptor subtype ligands
MERCK SHARP & DOHME14 citations73
US6087348AJul 11, 2000
Use of NK-1 receptor antagonists for treating stress disorders
MERCK SHARP & DOHME3 citations63
US5919781AJul 6, 1999
Use of NK-1 receptor antogonists for treating substance use disorders
MERCK SHARP & DOHME5 citations63
US6613766B1Sep 2, 2003
Pentaaza-cyclopental[a]naphthalene derivatives as ligands for GABAa α5 receptors
MERCK SHARP & DOHME2 citations62
US6727249B2Apr 27, 2004
Azabicyclic ether derivatives and their use as therapeutic agents
MERCK SHARP & DOHME4 citations61
US6096729AAug 1, 2000
Use of NK-1 receptor antagonists for treating amnestic disorders
MERCK SHARP & DOHME0 citations52
US6613765B1Sep 2, 2003
Use of NK-1 receptor antagonists for treating major depressive disorders
MERCK SHARP & DOHME0 citations51
US5861407AJan 19, 1999
Tetrahydropyridine derivatives as dopamine receptor subtype ligands
MERCK SHARP & DOHME1 citations50
US5681836AOct 28, 1997
Methanesulfonate salts of antipsychotic benzofuran derivatives
MERCK SHARP & DOHME0 citations42
US7276607B2Oct 2, 2007
5-HT7 receptor antagonists
MERCK SHARP & DOHME0 citations40
US7592456B2Sep 22, 2009
Arylsulfonylnaphthalene derivatives as 5HT2A antagonists
MERCK SHARP & DOHME0 citations39